Gaucher Disease via the GBA1/GBA Gene
Use
This test is aimed at individuals who have a clinical or suspected diagnosis of Gaucher disease or are of Ashkenazi Jewish descent, who have a high carrier frequency. The test is also relevant for reproductive partners of individuals with a known pathogenic variant in the GBA1 gene.
Special Instructions
The test is offered with various specimen options. Stat testing option is available with a 25% surcharge.
Limitations
This test was developed and its performance characteristics validated by the laboratory as per CLIA and CAP guidelines but has not been FDA approved. Genetic testing should be used in conjunction with other clinical findings and biochemical testing.
Methodology
Sanger
Biomarkers
Result Turnaround Time
12-20 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided
